Gastric Motility Disorder Drug Market
Gastric Motility Disorder Drug Market Size, Share & Trends Analysis Report, By Type (Velusetrag, Ipamorelin, TD-8954, and Others), By Application (Hospital, Clinic, and Home Use) Forecast Period, (2026-2035)
Industry Overview
Gastric motility disorder drug market was valued at $514.0 million in 2025 and is projected to reach $868.0 million by 2035, growing at a CAGR of 5.4% during the forecast period (2026-2035). The global gastric motility disorder drug market is expanding as clinical recognition of functional gastrointestinal conditions improves across healthcare systems. Advances in diagnostic practices have enabled earlier identification and more consistent treatment initiation. Physicians are increasingly favoring pharmacological management to address chronic symptom burden and improve patient outcomes. Regulatory approvals for newer agents with differentiated safety profiles are supporting gradual market expansion. Prescription continuity in long-term care settings is further sustaining demand.
Market Dynamics
Rising Adoption of Targeted Prokinetic Therapies
The global gastric motility disorder drug market is witnessing a gradual shift toward targeted prokinetic agents with improved receptor selectivity and safety profiles. Increased clinical focus on minimizing cardiovascular and neurological side effects associated with older therapies is influencing prescribing patterns. Pharmaceutical companies are prioritizing molecules that demonstrate sustained efficacy in chronic management. This trend is further supported by ongoing post-approval studies and real-world evidence generation. Improved patient compliance is also contributing to steady demand growth. As a result, targeted therapies are strengthening their position within treatment protocols.
Expansion of Treatment Access in Emerging Markets
Emerging economies are becoming increasingly important to the gastric motility disorder drug market owing to improving healthcare infrastructure and diagnosis rates. Greater availability of generic formulations is enhancing treatment affordability across these regions. Governments and healthcare providers are expanding gastrointestinal disease awareness and screening initiatives. This has led to higher prescription volumes in both hospital and clinic settings. Additionally, rising urbanization and lifestyle changes are contributing to disease prevalence. Collectively, these factors are supporting long-term market expansion.
Market Segmentation
- Based on the type, the market is segmented into Velusetrag, Ipamorelin, TD-8954, and others.
- Based on the application, the market is segmented into hospital, clinic, and home use.
Velusetrag Segment to Lead the Market with the Largest Share
Growth in the gastric motility disorder drug market is supported by the clinical progress of Velusetrag as a selective therapeutic option. Its mechanism of action has demonstrated potential benefits in improving gastric emptying and symptom control in controlled settings. The drug’s advancement through clinical development has strengthened confidence among healthcare professionals. Ongoing research has further clarified its safety and tolerability profile. Increased visibility in scientific literature has contributed to greater acceptance within specialist practice. As a result, Velusetrag continues to play a meaningful role in shaping market dynamics.
Hospitals: A Key Segment in Market Growth
The hospital segment is contributing notably to market growth owing to its central role in diagnosing and managing complex gastric motility disorders. Hospitals serve as primary centers for advanced diagnostic procedures and specialist consultations. Higher patient inflow for gastrointestinal complaints has translated into consistent drug utilization in inpatient and outpatient settings. Multidisciplinary treatment approaches within hospitals support sustained prescription volumes. Access to formulary-listed medications further strengthens adoption rates. These structural advantages position hospitals as a key driver of demand within the market.
Regional Outlook
The global gastric motility disorder drug market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Growing Demand For Systematic Clinical Management in Europe
Market growth in Europe is supported by systematic clinical management of gastrointestinal disorders across public healthcare systems. Standardized treatment protocols have encouraged consistent use of prescription therapies. Strong academic involvement has promoted evidence-based adoption of newer drugs. Regulatory harmonization across countries has facilitated broader market access. Increasing collaboration between research institutions and pharmaceutical companies has strengthened the development pipeline. Together, these factors are contributing to stable expansion across the European market.
North America Region Dominates the Market with Major Share
The North American gastric motility disorder drug market is expanding owing to a well-established healthcare infrastructure and strong clinical research activity. The region benefits from early adoption of novel therapeutic agents supported by robust regulatory pathways. High awareness among clinicians has improved diagnosis and treatment initiation rates. Favorable reimbursement frameworks have reduced access barriers for approved medications. Concentration of pharmaceutical developers has accelerated innovation and commercialization. These regional characteristics collectively underpin market growth.
Market Players Outlook
The major companies operating in the global gastric motility disorder drug market include AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., and Roche Holding AG, among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In July 2025, Atmo Biosciences, a company commercializing the first global ingestible gas-sensing capsule that provides insights into gut health and microbiome function, announced that it had commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule in measuring gastrointestinal transit time in patients with suspected motility disorders.
- In March 2025, Gvoke VialDx (glucagon) from Xeris received FDA approval as a diagnostic aid to temporarily inhibit GI motility during radiologic exams in adults, supplied as a 1mg/0.2mL vial requiring dilution. Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of glucagon per 0.2mL.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global gastric motility disorder drug market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Gastric Motility Disorder Drug Market Sales Analysis – Type | Application ($ Million)
- Gastric Motility Disorder Drug Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Gastric Motility Disorder Drug Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Gastric Motility Disorder Drug Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Gastric Motility Disorder Drug Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Gastric Motility Disorder Drug Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Gastric Motility Disorder Drug Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Gastric Motility Disorder Drug Market Revenue and Share by Manufacturers
- Gastric Motility Disorder Drug Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Roche Holding AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- Global Gastric Motility Disorder Drug Market Sales Analysis by Type ($ Million)
- Velusetrag
- Ipamorelin
- TD-8954
- Others
- Global Gastric Motility Disorder Drug Market Sales Analysis by Application ($ Million)
- Hospital
- Clinic
- Home Use
- Regional Analysis
- North American Gastric Motility Disorder Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Gastric Motility Disorder Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Gastric Motility Disorder Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Gastric Motility Disorder Drug Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca PLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Avenacy, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ChironWells GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Concert Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Evoke Pharma, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gilead Sciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Helsinn Healthcare S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Janssen Pharmaceuticals (Johnson & Johnson)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Organon & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Salix Pharmaceuticals (Bausch Health Companies)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Targacept, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Theravance Biopharma, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Gastric Motility Disorder Drug Market Research And Analysis By Type, 2025–2035 ($ Million)
2. Global Velusetrag Gastric Motility Disorder Drug Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Ipamorelin Gastric Motility Disorder Drug Market Research And Analysis By Region, 2025–2035 ($ Million)
4. Global TD-8954 Gastric Motility Disorder Drug Market Research And Analysis By Region, 2025–2035 ($ Million)
5. Global Others Gastric Motility Disorder Drug Market Research And Analysis By Region, 2025–2035 ($ Million)
6. Global Gastric Motility Disorder Drug Market Research And Analysis By Application, 2025–2035 ($ Million)
7. Global Gastric Motility Disorder Drug Market For Hospital Research And Analysis By Region, 2025–2035 ($ Million)
8. Global Gastric Motility Disorder Drug Market For Clinic Research And Analysis By Region, 2025–2035 ($ Million)
9. Global Gastric Motility Disorder Drug Market For Home Use Research And Analysis By Region, 2025–2035 ($ Million)
10. Global Gastric Motility Disorder Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
11. North American Gastric Motility Disorder Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
12. North American Gastric Motility Disorder Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
13. North American Gastric Motility Disorder Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
14. European Gastric Motility Disorder Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
15. European Gastric Motility Disorder Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
16. European Gastric Motility Disorder Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
17. Asia-Pacific Gastric Motility Disorder Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
18. Asia-Pacific Gastric Motility Disorder Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
19. Asia-Pacific Gastric Motility Disorder Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
20. Rest of the World Gastric Motility Disorder Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Rest of the World Gastric Motility Disorder Drug Market Research and Analysis by Type, 2025–2035 ($ Million)
22. Rest of the World Gastric Motility Disorder Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Gastric Motility Disorder Drug Market Share By Type, 2025 Vs 2035 (%)
2. Global Velusetrag Gastric Motility Disorder Drug Market Share By Region, 2025 Vs 2035 (%)
3. Global Ipamorelin Gastric Motility Disorder Drug Market Share By Region, 2025 Vs 2035 (%)
4. Global TD-8954 Gastric Motility Disorder Drug Market Share By Region, 2025 Vs 2035 (%)
5. Global Others Gastric Motility Disorder Drug Type Market Share By Region, 2025 Vs 2035 (%)
6. Global Gastric Motility Disorder Drug Market Share By Application, 2025 Vs 2035 (%)
7. Global Gastric Motility Disorder Drug Market For Hospital Share By Region, 2025 Vs 2035 (%)
8. Global Gastric Motility Disorder Drug Market For Clinic Share By Region, 2025 Vs 2035 (%)
9. Global Gastric Motility Disorder Drug Market For Home Use Share By Region, 2025 Vs 2035 (%)
10. Global Gastric Motility Disorder Drug Market Research And Analysis By Region, 2025–2035 ($ Million)
11. US Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
12. Canada Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
13. UK Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
14. France Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
15. Germany Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
16. Italy Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
17. Spain Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
18. Russia Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
19. Rest of Europe Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
20. India Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
21. China Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
22. Japan Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
23. South Korea Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
24. Australia and New Zealand Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
25. ASEAN Economies Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
26. Rest of Asia-Pacific Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
27. Latin America Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
28. Middle East and Africa Gastric Motility Disorder Drug Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Gastric Motility Disorder Drug Market in 2025 is estimated to be around $514.0 million.
North America holds the largest share in the Gastric Motility Disorder Drug Market.
Leading players in the Gastric Motility Disorder Drug Market include AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., and Roche Holding AG, among others.
The Gastric Motility Disorder Drug Market is expected to grow at a CAGR of 5.4% from 2026 to 2035.
The Gastric Motility Disorder Drug Market growth is driven by rising prevalence of gastrointestinal motility disorders and increasing demand for effective prokinetic and targeted therapeutic treatments.
